Equibles does not estimate personal net worth.
Get an email with a short summary when Candel Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CADL alertsThe proxy statement of Candel Therapeutics, Inc. reports total compensation of $1,561,536 for Francesca Barone in fiscal 2025, including a base salary of $483,312. Disclosed compensation is on record for 5 fiscal years. Francesca Barone has spoken on 1 investor event across 1 company, most recently for Candel Therapeutics, Inc. on August 12, 2026. Candel Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Candel Therapeutics, Inc. includes Paul Peter Tak (CEO and Board Member), Charles Schoch (CFO), Jason Amello (CFO) and 7 others.
“So Candel Therapeutics is a biopharmaceutical company developing off-the-shelf viral immunotherapies. These drugs are aimed at local delivery to achieve systemic immunization.”
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Candel Therapeutics, Inc. (CADL) | M.D., Chief Scientific Officer | $483,312 | $1,561,536 |
| 2024 | Candel Therapeutics, Inc. (CADL) | M.D., Chief Scientific Officer | $443,303 | $726,222 |
| 2023 | Candel Therapeutics, Inc. (CADL) | M.D., Chief Scientific Officer | $413,005 | $706,876 |
| 2022 | Candel Therapeutics, Inc. (CADL) | M.D., Chief Scientific Officer | $362,192 | $908,302 |
| 2021 | Candel Therapeutics, Inc. (CADL) | M.D., Ph.D.Chief Scientific Officer | $259,728 | $364,797 |
